Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics has disclosed that they have reached an agreement with the U.S. Food and Drug Administration (FDA) to expedite the analysis of the Phase 3 trial, ORIGIN, for potential full approval of Atacicept in adults suffering from IgA nephropathy (IgAN). This collaboration aims to fast-track the review process and seeks to provide more efficient access to the treatment. Atacicept is being investigated as a potential therapy for IgAN, a condition impacting thousands of adults globally. The expedited analysis of the Phase 3 trial signifies an important step towards potentially offering this treatment to those in need sooner.